Novel agents in trials for AML quizartinib and gilteritinib

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=HoulIwPjR4E

At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Mark Levis, MD, PhD, from Sidney Kimmel Com...

Speaker: Mark Levis, Event: ESH AL 2018, Format: Interview, Subject: Acute Myeloid Leukemia, Field: Treatment, Medicines: Midostaurin, Medicines: Quizartinib, Medicines: Gilteritinib, inhibitors, genetics, IDH1, IDH2, metastasis, resistance, AML, triplet therapy, combination therapies, targeted, novel agents, clinical trials
#############################